title: Intravitreal bevacizumab for choroidal neovascularization secondary to choroidal osteoma.
authors.affiliation: Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Won Kyung
authors.initials: WK
authors.lastname: Song
authors.forename: Hyoung Jun
authors.initials: HJ
authors.lastname: Koh
authors.forename: Oh Woong
authors.initials: OW
authors.lastname: Kwon
authors.forename: Suk Ho
authors.initials: SH
authors.lastname: Byeon
authors.forename: Sung Chul
authors.initials: SC
authors.lastname: Lee
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001859:Bone Neoplasms / Q000150:complications*; D002830:Choroid Neoplasms / Q000150:complications*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D010016:Osteoma / Q000150:complications*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab